Intuitive Surgical (NASDAQ: ISRG) delivered a clean beat in the second quarter. Revenue hit $2.89 billion, topping consensus by roughly $67 million, while non-GAAP EPS of $2.80 came in $0.29 above estimates. The headline numbers are strong. The composition of the beat matters more than the magnitude. This was not a one-off quarter fueled by tariff refunds or easy comps. The core business accelerated.
Worldwide procedures grew 16% year over year. The da Vinci platform rose 15%, and the Ion endoluminal system surged 36%. Procedure volume is the engine that drives recurring revenue, and it is accelerating from the 15% da Vinci growth rate reported in Q1. Instruments and accessories revenue rose 18% to $1.73 billion, tracking procedure growth closely. Systems revenue climbed 19% to $685 million, supported by 468 da Vinci placements versus 395 a year ago. Of those, 246 were da Vinci 5 systems, up from 180 in Q2 2025. The installed base now sits at 11,710 systems, up 12%.
The da Vinci 5 mix shift is the most consequential trend in the quarter. The company placed 53% of its new systems as da Vinci 5 units, up from 46% in the year-ago period. That matters because da Vinci 5 carries a higher average selling price and likely drives higher per-procedure instrument revenue over time. The 254 systems placed under operating leases, including 131 usage-based leases, suggest hospitals remain capital-constrained but willing to pay for access. That leasing model smooths revenue but defers system margin recognition. It is a trade-off that works when procedure growth is steady.
Non-GAAP gross margin expanded to 70.0% from 67.9% a year ago, a 210bp improvement. The company attributed the gain to operating leverage and a $28 million benefit from IEEPA tariff refunds, which added roughly $0.08 to EPS. Strip that out, and non-GAAP EPS would have been about $2.72, still a $0.21 beat. The underlying margin story is one of scale: higher procedure volumes and system placements are absorbing fixed costs in manufacturing and service infrastructure.
Full-year 2026 guidance was reiterated, not raised, despite the beat. Management expects da Vinci procedure growth of 13.5% to 15.5%, with a midpoint bias. Non-GAAP gross margin is forecast at 68% to 69%, including an estimated 1% tariff headwind. Non-GAAP operating expense growth is pegged at 11% to 13%. The decision to hold guidance steady despite a Q2 beat that could have justified a raise signals caution. The tariff refund was a one-time item, and the company explicitly warns that additional tariffs beyond current expectations could materially impact results. Management is not declaring victory.
The buyback pace was modest: $380 million for 0.9 million shares in the quarter. With $8.63 billion in cash and investments, Intuitive has ample firepower for M&A or larger repurchases. The lack of aggressive buyback activity suggests management sees better uses for capital, likely in R&D and commercial expansion, particularly for Ion and the emerging digital solutions portfolio.
What to watch in the second half is whether da Vinci 5 placements sustain their current mix and whether Ion procedure growth can maintain its 36% trajectory. Ion's installed base grew 21% to 1,096 systems, but procedure growth outpaced base growth, indicating utilization per system is rising. That is a healthy sign for a platform still early in its adoption curve. The guidance midpoint implies H2 procedure growth decelerates slightly from Q2's 15% da Vinci rate. If Q3 comes in above that midpoint, the reiterated guidance will look conservative. If it slips, the tariff and macro caution will have been prescient.